159 related articles for article (PubMed ID: 23018214)
21. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy.
Huntsman D; Resau JH; Klineberg E; Auersperg N
Am J Pathol; 1999 Aug; 155(2):343-8. PubMed ID: 10433927
[TBL] [Abstract][Full Text] [Related]
22. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
23. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.
Zhang GY; Ahmed N; Riley C; Oliva K; Barker G; Quinn MA; Rice GE
Br J Cancer; 2005 Jan; 92(1):113-9. PubMed ID: 15583697
[TBL] [Abstract][Full Text] [Related]
25. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
26. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
27. Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
[TBL] [Abstract][Full Text] [Related]
28. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
29. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
Fischer-Colbrie J; Witt A; Heinzl H; Speiser P; Czerwenka K; Sevelda P; Zeillinger R
Anticancer Res; 1997; 17(1B):613-9. PubMed ID: 9066588
[TBL] [Abstract][Full Text] [Related]
30. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases.
Tang S; Onuma K; Deb P; Wang E; Lytwyn A; Sur M; Daya D
Int J Gynecol Pathol; 2012 Mar; 31(2):103-10. PubMed ID: 22317864
[TBL] [Abstract][Full Text] [Related]
31. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.
Nassir M; Darb-Esfahani S; Richter R; Chekerov R; Hall C; Muallem MZ; Denkert C; Stamatian F; Fotopoulou C; Sehouli J; Braicu EI
Anticancer Res; 2013 Apr; 33(4):1673-7. PubMed ID: 23564814
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study.
Köbel M; Kalloger SE; Baker PM; Ewanowich CA; Arseneau J; Zherebitskiy V; Abdulkarim S; Leung S; Duggan MA; Fontaine D; Parker R; Huntsman DG; Gilks CB
Am J Surg Pathol; 2010 Jul; 34(7):984-93. PubMed ID: 20505499
[TBL] [Abstract][Full Text] [Related]
34. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
35. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer.
Amsterdam A; Shezen E; Raanan C; Schreiber L; Prus D; Slilat Y; Ben-Arie A; Seger R
Int J Oncol; 2011 Sep; 39(3):649-56. PubMed ID: 21687944
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
Kalir T; Rahaman J; Hagopian G; Demopoulos R; Cohen C; Burstein DE
Arch Pathol Lab Med; 2005 May; 129(5):651-4. PubMed ID: 15859637
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
McCluggage WG; Strand K; Abdulkadir A
Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
[TBL] [Abstract][Full Text] [Related]
38. Mammaglobin expression in gynecologic adenocarcinomas.
Hagemann IS; Pfeifer JD; Cao D
Hum Pathol; 2013 Apr; 44(4):628-35. PubMed ID: 23084633
[TBL] [Abstract][Full Text] [Related]
39. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
Nezhat FR; Apostol R; Nezhat C; Pejovic T
Am J Obstet Gynecol; 2015 Sep; 213(3):262-7. PubMed ID: 25818671
[TBL] [Abstract][Full Text] [Related]
40. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]